Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Founded in 1993 and headquartered in Frauenfeld, Switzerland, DocMorris AG primarily manages digital pharmacies alongside a wholesale division specializing in pharmaceuticals and health-related merchandise, operating within Switzerland and across international markets. Its product portfolio encompasses both prescription-required and over-the-counter medications, and also includes consumer health products, beauty and personal care items, nutritional supplements, pain relievers, and first aid provisions. Furthermore, it offers medicine management services. Complementing its online activities, the company also runs physical pharmacy outlets. Sales are conducted directly to medical practitioners, through other online mail-order pharmacies, and to private individuals, under brands such as Zur Rose, PromoFarma, TeleClinic, and DocMorris. Known as Zur Rose Group AG until May 2023, the company subsequently rebranded as DocMorris AG.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is reasonably priced on P/FCF.
Target Price
The average target price of DOCM.SW is 12.2 and suggests 8.71% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation t